Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › Vermillion's Aspira Labs Wins Coverage from BCBS of Michigan for OVA1

Vermillion's Aspira Labs Wins Coverage from BCBS of Michigan for OVA1

Mar 02, 2017
|
staff reporter

NEW YORK (360Dx) – Vermillion said yesterday that Blue Cross Blue Shield (BCBS) of Michigan has agreed to cover its OVA1 ovarian cancer test.

BCBS of Michigan covers more than 6 million people in Michigan and the larger Great Lakes region.

Valerie Palmieri, president and CEO of Vermillion, said in a statement that the company continues to execute on its managed care strategy and that Michigan and the surrounding region are an area of focus for its commercialization efforts.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. United Airlines Launches COVID-19 Testing Program for Travelers to Hawaii

  2. BioReference Settles False Claims, Kickback Allegations for $11.5M

  3. FDA Grants Emergency Use Authorizations for Quadrant Biosciences, KimForest Coronavirus Tests

  4. FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

  5. Vela Diagnostics Receives Second FDA Emergency Use Authorization for SARS-CoV-2 Molecular Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.